Text Search: Search by:

Refine your search with filters

Year:

All

Congress Abstracts

Tools & Skills

Publications

Congress Presentations

Videos & Podcasts

Quicksearch

DOP037: Excess steroid use in IBD: too much, how much, and why? Results from a UK nationwide auditECCO '16 Amsterdam

Year: 2016

Authors:

T. Raine¹, A. Bassi², E. Fogden³, B. Hayee⁴, J. K. Limdi⁵, H. Ludlow⁶, S. McLaughlin⁷, G. C. Parkes⁸, P. Patel⁹, M. Smith¹⁰, C. Selinger*¹¹

¹Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology Research, Cambridge, United Kingdom, ²Whiston Hospital, Department of Gastroenterology, Prescot, United Kingdom, ³Sandwell District General Hospital, Department of Gastroenterology, West Bromwich, United Kingdom, ⁴King’s College Hospital, Department of Gastroenterology, London, United Kingdom, ⁵Pennine Acute Hospitals NHS Trust, Department of Gastroenterology, Manchester, United Kingdom, ⁶University Hospital Llandough, Department of Gastroenterology, Penarth, Cardiff, United Kingdom, ⁷Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom, ⁸Barts and The London, Queen Mary’s School of Medicine and Dentistry, Department of Gastroenterology, London, United Kingdom, ⁹Epsom General Hospital, Department of Gastroenterology, Epsom, United Kingdom, ¹⁰Brighton and Sussex University Hospitals Trust, Digestive Diseases, Hove, East Sussex, United Kingdom, ¹¹St James University Hospital, Gastroenterology, Leeds, United Kingdom

DOP038: Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

T. Van Stappen*¹, L. Bollen¹, N. Vande Casteele¹, K. Papamichail^{1, 2},  N. Geukens¹, C. Barthel³, Y. Kölmel³, N. Zali³, S. Rameil³, G. Van Assche², M. Ferrante², S. Vermeire², A. Gils¹

¹KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium, ³R-Biopharm AG, Darmstadt, Germany

DOP039: Point-of-care monitoring of infliximab trough levels in capillary fingerstick blood of patients with inflammatory bowel disease (IBD)ECCO '16 Amsterdam

Year: 2016

Authors:

J. Maljaars*¹, C. de Dood², S. van der Burg¹, A. van der Meulen¹, H. Tanke², P. Corstjens²

¹LUMC, Gastroenterology-Hepatology, Leiden, Netherlands, ²Leiden University Medical Centre, Department of Molecular Cell Biology Geb. 1, Leiden, Netherlands

DOP040: Effects of education and information on vaccination behaviour in IBD patientsECCO '16 Amsterdam

Year: 2016

Authors:

S. Coenen*¹, E. Weyts¹, C. Jorissen², P. De Munter³, M. Noman¹, V. Ballet¹, S. Vermeire¹, G. Van Assche¹, M. Ferrante¹

¹UZ Leuven, Gastroenterology, Leuven, Belgium, ²KU Leuven, Leuven, Belgium, ³UZ Leuven, Leuven, Belgium

DOP041: Impact of an education programme on IBD patient’s skills: one year results of the ECIPE randomised, controlled multicentre study.ECCO '16 Amsterdam

Year: 2016

Authors:

J. Moreau¹, L. Marthey², C. Trang³, M. Nachury⁴, R. Altwegg⁵, J.-C. Grimaud⁶, S. Orempuller¹, J. Filippi⁷, A. Aubourg⁸, C. Baudry⁹, P. Seksik¹⁰, X. Roblin¹¹, S. Nahon¹², G. Savoye¹³, B. Mesnard¹⁴, C. Stefanescu¹⁵, M. Simon¹⁶, B. Coffin¹⁷, J.-L. Dupas¹⁸, S. Chevret¹⁹, M. Allez*²⁰

¹Rangueil Hospital, Department of Gastroenterology, Toulouse, France, ²Bicetre Hospital, Department of Gastroenterology, Le Kremlin Bicêtre, France, ³CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, ⁴Huriez Hospital, Department of Gastroenterology, Lille, France, ⁵Saint Eloi Hospital, Department of Hepatology and Gastroenterology, Montpellier, France, ⁶Nord Hospital, Department of Gastroenterology, Marseille, France, ⁷Archet Hospital, Department of Gastroenterology and Nutrition, Nice, France, ⁸Trousseau University Hospital, Department of Gastroenterology, Tours, France, ⁹Saint-Louis Hospital, Department of Gastroenterology and Hepatology, Paris, France, ¹⁰St. Antoine Hospital, Department of Gastroenterology, Paris, France, ¹¹CHU St Etienne, Department of Gastroenterology, Saint-Etienne, France, ¹²Montfermeil Hospital, Department of Gastroenterology, Montfermeil, France, ¹³Charles Nicolle Hospital, Department of Gastroenterology, Rouen, France, ¹⁴CH Dron, Department of Gastroenterology, Tourcoing, France, ¹⁵Beaujon Hospital, Department of Gastroenterology, Paris, France, ¹⁶Montsouris Mutualist Institute, Department of Gastroenterology, Paris, France, ¹⁷Louis Mourier Hospital APHP, Department of Gastroenterology and Hepatology, Colombes, France, ¹⁸Nord Hospital, Department of Gastroenterology, Amiens, France, ¹⁹Saint-Louis Hospital, Department of Biostatistics, Paris, France, ²⁰Saint-Louis Hospital, Department of Gastroenterology, Paris, France

DOP042: Most anti-TNF injectors are stored under suboptimal conditions at homeECCO '16 Amsterdam

Year: 2016

Authors:

M. de Jong^{*1, 2}, M. Pierik^{1, 2}, A. Peters³, M. Roemers⁴, F. van der Heijden⁵, V. Hilhorst⁶, A. van Tubergen^{7, 8}

¹Maastricht University Medical Centre+, Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre+, NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre+, Department of Internal Medicine, Maastricht, Netherlands, ⁴AntTail, Utrecht, Netherlands, ⁵MSD, Haarlem, Netherlands, ⁶Maastricht University Medical Centre+, Department of Clinical Pharmacy & Toxicology, Maastricht, Netherlands, ⁷Maastricht University Medical Centre+, Department of Internal Medicine, division of Rheumatology, Maastricht, Netherlands, ⁸Maastricht University Medical Centre+, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands

DOP043: Nonadherence to anti-TNF therapy predicts clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre studyECCO '16 Amsterdam

Year: 2016

Authors:

M. van der Have*¹, B. Oldenburg¹, A. A. Kaptein², J. M. Jansen³, R. C. Scheffer⁴, S. A. van Tuyl⁵, A. E. van der Meulen - de Jong⁶, M. Pierik⁷, P. D. Siersema¹, M. G. van Oijen^{1, 8}, H. H. Fidder¹

¹University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ²Leiden University Medical Centre, Section Medical Psychology, Leiden, Netherlands, ³Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ⁴Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, ‘s Hertogenbosch , Netherlands, ⁵Diakonessenhuis, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ⁶Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ⁷Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁸Academic Medical Centre, Department of Medical Oncology, Amsterdam, Netherlands

DOP044: Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel diseaseECCO '16 Amsterdam

Year: 2016

Authors:

K. Carlsen*^{1, 2}, C. Jakobsen², L. F. Hansen², A. Paerregaard², L. B. Riis³, P. S. Munkholm⁴, V. Wewer²

¹Hvidovre Hospital, Paediatric, Hvidovre, Denmark, ²Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, ³Herlev Hospital, Department of Pathology, Herlev, Denmark, ⁴North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

DOP045: Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel DiseaseECCO '16 Amsterdam

Year: 2016

Authors:

K. Carlsen*^{1, 2}, C. Jakobsen², L. F. Hansen², A. Paerregaard², T. Kallemose³, G. Houen⁴, L.B. Riis⁵, P. S. Munkholm⁶, V. Wewer²

¹Hvidovre Hospital, Paediatric, Hvidovre, Denmark, ²Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, ³Hvidovre Hospital, Clinical Research Centre and Department of Orthopaedic, Hvidovre, Denmark, ⁴Statens Serum Institute, Department of Autoimmunology and Biomarkers, Copenhagen, Denmark, ⁵Herlev Hospital, Department of Pathology, Herlev, Denmark, ⁶North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

DOP046: Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1 189 patients with Crohn’s disease: a multicentre cohort studyECCO '16 Amsterdam

Year: 2016

Authors:

H. Tanaka*¹, N. Kamata², A. Yamada³, K. Endo⁴, T. Fujii⁵, T. Yoshino^{6, 7}, T. Sugaya⁸, Y. Yokoyama⁹, S. Bamba¹⁰, J. Umeno¹¹, Y. Yanai¹², M. Ishii¹³, T. Kawaguchi¹⁴, S. Shinzaki¹⁵, Y. Toya¹⁶, T. Kobayashi¹⁷, M. Nojima¹⁸, T. Hibi¹⁷

¹Sapporo Kosei General Hospital, IBD Centre, Sapporo, Japan, ²Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, ³Sakura Medical Centre, Toho University, Department of Internal Medicine, Chiba, Japan, ⁴Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan, ⁵Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, ⁶Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, ⁷Tazuke Kofukai Medical Research Institute, Kitano Hospital, IBD Centre, Osaka, Japan, ⁸Dokkyo Medical University, Department of Gastroenterology, Tochigi, Japan, ⁹Hyogo College of Medicine, Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, ¹⁰Shiga University of Medical Science, Division of Gastroenterology, Shiga, Japan, ¹¹Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, ¹²Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, ¹³Kawasaki Medical School, Department of Internal Medicine, Division of Gastroenterology, Kurashiki, Japan, ¹⁴Tokyo Yamate Medical Centre, Department of Internal Medicine, Division of IBD, Tokyo, Japan, ¹⁵Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan, ¹⁶School of Medicine, Iwate Medial University, Division of Gastroenterology, Iwate, Japan, ¹⁷Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan, ¹⁸The Institute of Medical Science, The University of Tokyo, Centre for Translational Research, Tokyo, Japan

DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease—results at year 7ECCO '16 Amsterdam

Year: 2016

Authors:

G. D’Haens¹, W. Reinisch*², J. Satsangi³, E. Loftus Jr⁴, R. Panaccione⁵, H. Read⁶, M. Heinrich⁷, J. Petersson⁶, A.M. Robinson⁶

¹Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, ²Medical University of Vienna, Vienna, Austria, ³Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, ⁴Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, ⁵University of Calgary, Department of Medicine, Calgary, Canada, ⁶AbbVie Inc., North Chicago, Illinois, United States, ⁷AbbVie Deutschland, Ludwigshafen, Germany

DOP048: Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome—post-hoc analyses from the PURSUIT programmeECCO '16 Amsterdam

Year: 2016

Authors:

J.-F. Colombel*¹, W. Reinisch², P. Gibson³, W. J. Sandborn⁴, B. Feagan⁵, S. Xu⁶, R. Strauss⁶, H. Zhang⁶, D. Tarabar⁷, Z. Hebzda⁸, P. Rutgeerts⁹, C. Marano⁶

¹Mount Sinai, Icahn School of Medicine, New York, New York, United States, ²Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, ³Alfred Hospital, Melbourne, Australia, ⁴University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, ⁵Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, ⁶Janssen R & D, LLC, Spring House, Pennsylvania, United States, ⁷Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia, ⁸Military Hospital, Krakow, Poland, ⁹University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands

DOP049: Efficacy and safety of golimumab induction  for moderate-to-severe ulcerative colitis in  the United Kingdom: results from the  GO-COLITIS studyECCO '16 Amsterdam

Year: 2016

Authors:

C. Probert*¹, D. R. Gaya², P. J. Hamlin³, P. Irving⁴, S. Sebastian⁵, G. Gillespie⁶, H. Tate⁶, C. Wheeler⁶

¹University of Liverpool, Liverpool, United Kingdom, ²Glasgow Royal Infirmary, Glasgow, United Kingdom, ³Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁴Guy’s and St. Thomas’ Hospitals, London, United Kingdom, ⁵Hull & East Yorkshire NHS Trust, Hull, United Kingdom, ⁶MSD UK, Hoddesdon, United Kingdom

DOP050: The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohn’s disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studiesECCO '16 Amsterdam

Year: 2016

Authors:

G. D’Haens¹, J.-F. Colombel*², M. Dubinsky², B. Abhyankar³, A. James³, K. Lasch⁴

¹Academic Medical Centre, Amsterdam, Netherlands, ²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, ³Takeda Development Centre Europe Ltd, London, United Kingdom, ⁴Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois, United States

DOP051: Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

E.V. Loftus Jr¹, J.-F. Colombel^*2, A. Previtali³, M. Smyth³

¹Mayo Clinic, Rochester, Minnesota, United States, ²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, ³Takeda Development Centre Europe Ltd, London, United Kingdom

DOP052: Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

W. Sandborn*¹, B. Feagan², G. D’Haens³, B. Levesque⁴, R. Pai⁵, S. Hanauer⁶, D. Wolf⁷, S. Vermeire⁸, S. Ghosh⁹, H. Smith¹⁰, M. Cravets¹⁰, P. Frohna¹⁰, S. Gujrathi¹⁰, R. Aranda¹⁰, A. Olson¹⁰

¹University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, ²Western University/Robarts Research Institute, Robarts Clinical Trials Inc., London, Ontario, Canada, ³Academic Medical Centre (AMC), Amsterdam, Netherlands, ⁴Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada, ⁵Mayo Clinic, Scottsdale, Arizona, United States, ⁶Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, ⁷Atlanta Gastroenterology Associates, Atlanta, Georgia, United States, ⁸University of Leuven, Leuven, Belgium, ⁹University of Calgary, Calgary, Canada, ¹⁰Receptos, Inc., San Diego, California, States

DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohn’s disease: results of 2 Phase 2b randomised placebo-controlled trialsECCO '16 Amsterdam

Year: 2016

Authors:

J. Panés*¹, M. Moscariello², E. Maller², G. Chan², W. Wang², P. Healey³

¹Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ²Pfizer Inc, Collegeville, United States, ³Pfizer Inc, Groton, Connecticut, United States

DOP054: Discrepancies between patient-reported outcomes, endoscopic, and histologic appearance in ulcerative colitisECCO '16 Amsterdam

Year: 2016

Authors:

J.-F. Colombel*¹, M. Keir², A. Scherl², R. Zhao², G. de Hertogh³, W. Faubion⁴, T. Lu²

¹Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States, ²Genentech, South San Francisco, California, United States, ³Department of Imaging and Pathology, Catholic University of Leuven, Leuven, Belgium, ⁴Mayo Clinic Rochester, Department of Gastoenterology, Rochester, Minnesota, United States

DOP055: Azithromycin based therapy for induction of remission in mild to moderate active paediatric Crohn’s disease: the Multicentre azithromycin for Crohn’s disease AZCRO trialECCO '16 Amsterdam

Year: 2016

Authors:

A. Levine*^{1, 2}, J. Kierkuś³, M. Kori⁴, M. Sladek⁵, R. Sigall Boneh¹, J. Escher⁶, E. Wine⁷, B. Yerushalmi⁸, J. Amil Dias⁹, R. Shaul¹⁰, A. Akriv¹¹, D. Zucker¹¹, D. Turner^{11, 12}

¹Wolfson Medical Centre, Paediatric Gastroenterology and Nutrition Unit, Tel-Aviv, Israel, ²Tel Aviv University, Tel-Aviv, Israel, ³The Children’s Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, ⁴Kaplan Medical Centre, Paediatric Day Care Unit, Rehovot, Israel, ⁵Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, ⁶Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ⁷University of Alberta, Division of Paediatric Gastroenterology, Department of Paediatrics, Edmonton, Canada, ⁸Soroka Medical Centre, Ben Gurion University of the Negev, Paediatric Gastroenterology, Beer-Sheva, Israel, ⁹Hospital, S. João, Department of Paediatrics, Porto, Portugal, ¹⁰Meyer Children’s Hospital, Gastroenterology Unit, Haifa, Israel, ¹¹The Hebrew University of Jerusalem, Jerusalem, Israel, ¹²Shaare Zedek Medical Centre, The Juliet Keidan Institute of Paediatric Gastroenterology & Nutrition, Jerusalem, Israel

DOP056: Pharmacokinetics and exposure-response relationships of golimumab in paediatric patients with moderate-to-severe ulcerative colitis: results from a multicentre open-label studyECCO '16 Amsterdam

Year: 2016

Authors:

O. J. Adedokun*¹, D. Chan¹, L. Padgett¹, Y. Xu¹, J. Hyams², D. Turner³, Z. Xu¹, H. Davis¹, R. Strauss¹

¹Janssen R & D, LLC, Spring House, Pennsylvania, United States, ²Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, ³The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Centre, Jerusalem, Israel